Suzhou Zion Pharma Technology Co. Ltd. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.

Researchers at Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. have divulged GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

SK Biopharmaceuticals Co. Ltd. has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Ildong Pharmaceutical Co. Ltd. has described GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Sunshine Lake Pharma Co Ltd. has identified pyrimidopyridine compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Ildong Pharmaceutical Co. Ltd. has identified novel tetraheterocycle compounds acting as GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Chengdu Origiant Pharmaceutical Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified pyrimidine-containing polycyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.